Contract Option Exercises — February 24, 2026

Two awards totaling $209M to MAPP and Medicines Company signal robust HHS BARDA support for anti-infectives and Marburg immunotherapy, with $98M already outlayed and options to $299M+ through 2036.

$94M firm-fixed price order to veteran-owned VES underscores competitive edge in disability exams, with 11% ($10M) outlayed post-performance end.

Qlarant's $175M CMS data processing award from 2005 shows $0 outlay and expired 2020 period, flagging funding/execution voids.

Low outlays vs obligations: $0 on $175M Qlarant, 48% on $98M Medicines, 53% on $111M MAPP, 11% on $94M VES signal potential funding delays or shortfalls.

Expired performance periods on Qlarant (2020) and VES (2020) without extensions heighten re-compete risks despite full/open competition wins.

Unexercised options and remaining outlays: $188M across MAPP ($299M pot.), Medicines ($54M remain.), VES ($84M remain.) through 2030-2036.

BARDA's focus on infectious disease countermeasures (Marburg, anti-infectives) amid biothreat preparedness, favoring small/disadvantaged biopharma winners.

75% of value ($383M) in HHS awards, with 50%+ ($209M) to BARDA biotech R&D for viral/infectious threats, showing multi-year commitments to small firms.

VA's $94M veteran-owned award amid low outlay flags steady demand for disability evals despite execution lags.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M obligated with $299M option potential to 2036; highest growth upside in Marburg R&D.", "trigger"=>"Option exercise notifications or outlay >$100M"}

{"entity"=>"Qlarant Integrity Solutions", "reason"=>"$175M obligation with $0 outlay post-2020 expiry signals distress or wind-down.", "trigger"=>"Any outlay increase or follow-on CMS award"}

{"entity"=>"BARDA Infectious Disease Pipeline", "reason"=>"Concentrated $209M in anti-infectives/Marburg amid biodefense trends.", "trigger"=>"New BARDA awards or HHS budget hikes"}